MINT-CANDESARTAN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CANDESARTAN CILEXETIL

Pieejams no:

MINT PHARMACEUTICALS INC

ATĶ kods:

C09CA06

SNN (starptautisko nepatentēto nosaukumu):

CANDESARTAN

Deva:

32MG

Zāļu forma:

TABLET

Kompozīcija:

CANDESARTAN CILEXETIL 32MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

30/100/1000

Receptes veids:

Prescription

Ārstniecības joma:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0135220004; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2018-06-05

Produkta apraksts

MINT-CANDESARTAN Product Monograph
Page 1 of 34
PRODUCT MONOGRAPH
PR
MINT-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Mint Pharmaceuticals Inc., DATE OF REVISION:
6575 Davand Drive
November 29, 2022
Mississauga, Ontario
L5T 2M3
Submission
Control No: 265629
MINT-CANDESARTAN Product Monograph
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...........................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS
....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE REACTIONS
....................................................................................................
8
DRUG
INTERACTIONS....................................................................................................13
DOSAGE AND
ADMINISTRATION.................................................................................14
OVERDOSAGE
.................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
................................................................17
STORAGE AND
STABILITY............................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................20
PART II: SCIENTIFIC
INFORMATION................................................................................21
PHARMACEUTICAL
INFORMATION.............................................................................21
CLINICAL TRIALS
..........................................................................................